Struggling From Price Cuts, Korea’s Dong-A Looks To Change Course
This article was originally published in PharmAsia News
Executive Summary
Korea’s top pharma company saw flat sales and a drop in profits in the third quarter, showing the impact of industry-wide price cuts. GSK holds a 10% stake in Dong-A.
You may also be interested in...
Dong-A Pharmaceutical, Meiji Seika Pharma Join For Biosimilar Distribution In Japan And Korea
SEOUL - South Korea's leading pharma company Dong-A Pharmaceutical Co. will join the biosimilar sector, years behind its domestic competitors. The company signed a memorandum of understanding with the Korean authorities to build a biosimilar plant in collabration with Japan's Meiji Seika Pharma Co. Ltd. at the Songdo Free Economic Zone in Incheon City, about 10 miles west of Seoul
Korea Allows Sales Of OTC Products In Supermarkets July 21, But Distribution Remains A Challenge
SEOUL - South Koreans are expected to be able to purchase 48 new over-the-counter products at supermarkets and conveniences stores, previously only available at pharmacies, beginning July 21, but consumers found that companies need more time to allow for the expanded distribution and manufacturing
Dong-A Enrolls GSK Korea General Manager On Board Of Directors; GSK Says Move Will Strengthen Alliance, Not Influence
SEOUL - Korea's leading pharma Dong-A Pharmaceutical Co. Ltd. placed GlaxoSmithKline PLC's Korea General Manager Kim Jin-ho on its nine-member board of directors in a follow-up action to GSK's acquisition of a 9.9% stake in Dong-A in May 2010